Displaying 11 (all) recruiting clinical trials.
-
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
This study wants to see if a new immunotherapy treatment called ONC-392, combined with Lu 177 vipivotide (Pluvicto) compared to Lu 177 vipivotide (Pluvicto) alone ...